More than half a dozen major drugmakers are participating in the Trump administration’s expedited FDA review program, but several leading firms are hesitant due to potential legal and safety risks, Reuters’ Maggie Fick and Patrick Wingrove report. Executives cited concerns that a two month review could compromise scientific rigor, undermine FDA credibility, and expose companies to litigation if serious side effects emerge after approval, according to the report. Publicly traded companies in the space include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- White House releases details on Trump ‘Great Healthcare Plan’
- Johnson & Johnson’s tecvayli shows efficacy in Phase 3 multiple myeloma study
- Trump Trade: Trump administration moves to end pharma trade probe
- Trump administration moves to end U.S. pharma trade probe, Endpoints News says
- J&J announces new longer follow-up results from Phase 1b/2 OrigAMI-1 study